Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

Dr. Saha continued, "We are thrilled to now be progressing all three of our most advanced pipeline programs in clinical studies focused on areas with significant unmet need, including hemophilia B, sleep-wake disorders, and solid tumors. With our recently strengthened balance sheet, we believe we are well positioned to execute on our clinical plans through multiple clinical readouts." Recent Highlights Anticipated Upcoming Program Milestones BOSTON and LONDON, May 13, 2024 (GLOBE NEWSWIRE) -- Centessa Pharm ...